top of page

CEO Dr. Yona Geffen attends Bio-Europe in Vienna

3-5 November 2025

Our CEO, Dr. Yona Geffen attended BioEurope in Vienna, Austria a global hub of scientific innovation and investment in life sciences.


There was active participation in a dynamic and content-rich conference filled with colleagues and professionals with opportunities to connect, explore meaningful partnerships, strategic collaborations, and advance financing in stem cell therapy to drive innovation forward.

Next
Cytora bottom logo

MENU

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

ABOUT US

TECHNOLOGY

PIPELINE

TEAM

PUBLICATIONS

NEWS AND EVENTS

CONTACT US

CONTACT US

info@cytorastem.com

© 2022 Cytora. All rights reserved.

bottom of page